04/01/2022 Lenvatinib and sorafenib for treating differentiated thyroid cancer
The Ministry of Health’s Drug Advisory Committee has recommended:
- Sorafenib 200 mg tablet; and
- Lenvatinib 4 mg and 10 mg capsules
for treating locally advanced or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
Subsidy status
RSorafenib 200 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication with effect from 4 January 2022.
RLenvatinib 4 mg and 10 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 1 September 2022.
Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.